Approach to the Patient With Moderate Hypertriglyceridemia

J Clin Endocrinol Metab. 2022 May 17;107(6):1686-1697. doi: 10.1210/clinem/dgac085.

Abstract

Hypertriglyceridemia is a common lipid disorder encountered in clinical practice. Plasma triglycerides are a marker for the concentration of triglycerides carried in chylomicrons and very low-density lipoprotein particles. A fasting triglyceride level <150 mg/dL is accepted widely as the upper limit of normal range. Guidelines for hypertriglyceridemia are variable without a global consensus on classification and goals for triglyceride levels. A general classification of hypertriglyceridemia is mild < 200 mg/dL, moderate = 200 to 500 mg/dL, moderate to severe = 500 to 1000 mg/dL, and severe > 1000 mg/dL. Because moderate hypertriglyceridemia does increase atherosclerotic cardiovascular disease risk, it is important to determine the underlying etiology to guide appropriate and timely management. This article provides stepwise recommendations on the diagnosis and management of moderate hypertriglyceridemia, based on 3 common scenarios encountered in clinical practice. Initial steps in management include evaluating for secondary contributors, especially diabetes mellitus. Based on patient characteristics, appropriate management decisions include lifestyle adjustments aimed at weight loss and decreasing alcohol consumption and use of statin and nonstatin therapies.

Keywords: ASCVD; apolipoprotein B; combined hyperlipidemia; dysbetalipoproteinemia; dyslipidemia; fibrates; fish oil; lifestyle; pancreatitis; triglycerides.

MeSH terms

  • Atherosclerosis* / drug therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Hyperlipidemias* / drug therapy
  • Hypertriglyceridemia* / complications
  • Hypertriglyceridemia* / diagnosis
  • Hypertriglyceridemia* / therapy
  • Triglycerides

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides